Hugo Salinas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hugo Salinas has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Alejandra Schüle
Gynecology Service, Second Chair of Gynecology, Faculty of Medical Sciences, National University of Córdoba, University Hospital of Maternity and Neonatology, Córdoba, Argentina
1 shared publicationAlfredo San Martín O
Hospital Clínico Universidad de Chile. Departamento de Obstetricia y Ginecología
1 shared publication- Ana Lúcia Ribeiro Valadares
Department of Obstetrics and Gynecology, School of Medicine, State University of Campinas (UNICAMP), Campinas, Brazil
1 shared publication - Ascanio Bencosme
Facultad de Ciencias de la Salud, Universidad Autónoma de Santo Domingo, Santo Domingo, República Dominicana
1 shared publication - Carlos Escalante
Departamento de Ginecología, Facultad de Medicina, Universidad de Costa Rica, San José, Costa Rica
1 shared publication Carlos Salinas
Obstetrics and Gynecology Service, Ángeles Hospital, Puebla, Mexico
1 shared publication
Latest Publications
- 6 October 2026
- Published by Wolters Kluwer Health in Menopause
Awareness and clinical impact of the revised FDA warning on menopausal hormone therapy among Latin American physicians. REDLINC XIV
Objective: To evaluate Latin American physicians’ awareness regarding the recent revised statement of the US Food and Drug Administration (FDA) “black box warning” on menopausal hormone therapy (MHT) and to analyze its self-reported impact on clinical practice. Methods: A multicenter cross-sectional study was conducted in thirteen Latin American countries. Physicians caring for peri- and postmenopausal women completed an anonymous survey assessing awareness of the revised FDA communication, perceived clarity, self-reported impact on clinical practice, and MHT prescribing patterns. Bivariate analyses and multivariable logistic regression were performed. Results: A total of 2,166 physicians participated, mainly obstetrician-gynecologists (75.7%) and endocrinologists (9.0%). Overall, 80.7% were aware of the FDA revised statement. In addition, 90.5% considered that the previous warning had overestimated breast cancer risk, and 78.9% believed that the revised communication provides a more balanced view of risks and benefits. Changes in clinical practice were reported by 59.4% of participants, whereas 18.7% reported increased MHT prescribing. Furthermore, 53.3% modified the way they explain breast cancer risk, and 40.4% reported spending more time on patient education and shared decision-making. Physicians with ≤20 years of professional experience and those from specialties other than obstetrics and gynecology or endocrinology were more likely to report that the FDA revised statement would influence their therapeutic conduct. Conclusions: The revised FDA communication appears to have influenced Latin American physicians’ views and self-reported clinical practice, promoting a more balanced view of MHT and encouraging patient education and shared decision-making. However, the increase in MHT prescribing rates was relatively modest, and overall findings should be interpreted cautiously given the cross-sectional design, self-reported nature of the data, and potential selection bias.
- 6 October 2026
- Published by Wolters Kluwer Health in Menopause
Awareness and clinical impact of the revised FDA warning on menopausal hormone therapy among Latin American physicians. REDLINC XIV
Objective: To evaluate Latin American physicians’ awareness regarding the recent revised statement of the US Food and Drug Administration (FDA) “black box warning” on menopausal hormone therapy (MHT) and to analyze its self-reported impact on clinical practice. Methods: A multicenter cross-sectional study was conducted in thirteen Latin American countries. Physicians caring for peri- and postmenopausal women completed an anonymous survey assessing awareness of the revised FDA communication, perceived clarity, self-reported impact on clinical practice, and MHT prescribing patterns. Bivariate analyses and multivariable logistic regression were performed. Results: A total of 2,166 physicians participated, mainly obstetrician-gynecologists (75.7%) and endocrinologists (9.0%). Overall, 80.7% were aware of the FDA revised statement. In addition, 90.5% considered that the previous warning had overestimated breast cancer risk, and 78.9% believed that the revised communication provides a more balanced view of risks and benefits. Changes in clinical practice were reported by 59.4% of participants, whereas 18.7% reported increased MHT prescribing. Furthermore, 53.3% modified the way they explain breast cancer risk, and 40.4% reported spending more time on patient education and shared decision-making. Physicians with ≤20 years of professional experience and those from specialties other than obstetrics and gynecology or endocrinology were more likely to report that the FDA revised statement would influence their therapeutic conduct. Conclusions: The revised FDA communication appears to have influenced Latin American physicians’ views and self-reported clinical practice, promoting a more balanced view of MHT and encouraging patient education and shared decision-making. However, the increase in MHT prescribing rates was relatively modest, and overall findings should be interpreted cautiously given the cross-sectional design, self-reported nature of the data, and potential selection bias.
- Open Access
- 13 December 2021
- Published by Universidad de Chile in Revista Hospital Clínico Universidad de Chile
- Vol. 32 (3)
Histerectomía total vía abdominal: revisión de la literatura
Hysterectomy is the most common gynecological surgery in non-pregnant women. There are different surgical approaches for total hysterectomy, abdominal, vaginal, laparoscopic and robotic routes. The choice is determined by different factors such as uterine size, malformations, surgical risks, skill of the surgeon, expected postoperative quality of life, and monetary costs. The surgical technique is well described in the literature, however, there are certain anatomical and functional considerations that must be known before performing the hysterectomy to avoid complications. The most frequent complications are hemorrhage, infections, thromboembolism, urinary and gastrointestinal tract injuries. Majority can be avoided with an adequate procedure and management of pre-existing comorbidities.
- 13 December 2021
- Published by Universidad de Chile in Revista Hospital Clínico Universidad de Chile
- Vol. 32 (3)
Open AccessHisterectomía total vía abdominal: revisión de la literatura
Hysterectomy is the most common gynecological surgery in non-pregnant women. There are different surgical approaches for total hysterectomy, abdominal, vaginal, laparoscopic and robotic routes. The choice is determined by different factors such as uterine size, malformations, surgical risks, skill of the surgeon, expected postoperative quality of life, and monetary costs. The surgical technique is well described in the literature, however, there are certain anatomical and functional considerations that must be known before performing the hysterectomy to avoid complications. The most frequent complications are hemorrhage, infections, thromboembolism, urinary and gastrointestinal tract injuries. Majority can be avoided with an adequate procedure and management of pre-existing comorbidities.